ketorolac Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibufenac derivatives 1529 74103-06-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketorolac
  • ketorolac tromethamine
  • ketorolac trometamol
  • trometamol ketorolac
  • (+/-)-Ketorolac
  • keromin
A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.
  • Molecular weight: 255.27
  • Formula: C15H13NO3
  • CLOGP: 1.62
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 59.30
  • ALOGS: -2.70
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 200 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 58 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 9.79 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.35 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 30, 1989 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 530.36 34.73 154 595 46489 2310847
Eye irritation 123.66 34.73 29 720 3483 2353853
Punctate keratitis 123.21 34.73 18 731 145 2357191
Eye pain 99.44 34.73 26 723 4865 2352471
Corneal epithelium defect 90.55 34.73 13 736 91 2357245
Anterior chamber cell 87.03 34.73 12 737 60 2357276
Vision blurred 82.67 34.73 29 720 14639 2342697
Corneal oedema 74.71 34.73 13 736 339 2356997
Spinal epidural haematoma 74.56 34.73 11 738 95 2357241
Quadriplegia 73.25 34.73 13 736 381 2356955
Hypersensitivity 72.66 34.73 30 719 23563 2333773
Visual acuity reduced 69.63 34.73 20 729 5278 2352058
Anaphylactic reaction 69.56 34.73 23 726 9682 2347654
Acute kidney injury 67.58 34.73 30 719 28092 2329244
Extradural haematoma 62.94 34.73 11 738 294 2357042
Ocular hyperaemia 60.91 34.73 17 732 4039 2353297
Ulcerative keratitis 56.04 34.73 11 738 561 2356775
Drug interaction 51.01 34.73 25 724 29138 2328198
Drug ineffective 48.71 34.73 38 711 101586 2255750
Corneal abrasion 47.17 34.73 8 741 178 2357158
Foreign body sensation in eyes 46.39 34.73 9 740 431 2356905
Urinoma 45.00 34.73 6 743 22 2357314
Corneal disorder 41.48 34.73 8 741 371 2356965
Completed suicide 39.65 34.73 19 730 21015 2336321
Kounis syndrome 37.94 34.73 7 742 255 2357081
Angioedema 37.45 34.73 14 735 8382 2348954
Labelled drug-drug interaction medication error 36.62 34.73 9 740 1299 2356037
Drug abuse 35.91 34.73 15 734 12011 2345325
Nausea 35.30 34.73 33 716 112156 2245180
Purpura fulminans 34.93 34.73 5 744 34 2357302

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 105.52 48.55 35 422 15100 1731224
Ulcerative keratitis 100.94 48.55 17 440 364 1745960
Anaphylactic reaction 89.15 48.55 25 432 6088 1740236
Acute kidney injury 77.04 48.55 35 422 34909 1711415
Drug interaction 55.14 48.55 26 431 27932 1718392
Mixed liver injury 50.64 48.55 9 448 264 1746060
Angioedema 50.11 48.55 18 439 9646 1736678
Corneal oedema 48.85 48.55 9 448 324 1746000

Pharmacologic Action:

SourceCodeDescription
ATC M01AB15 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Acetic acid derivatives and related substances
ATC S01BC05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Antiinflammatory agents, non-steroids
ATC S01FB51 SENSORY ORGANS
OPHTHALMOLOGICALS
MYDRIATICS AND CYCLOPLEGICS
Sympathomimetics excl. antiglaucoma preparations
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
FDA Chemical/Ingredient N0000175721 Nonsteroidal Anti-inflammatory Compounds
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
FDA EPC N0000175939 Cyclooxygenase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Severe pain indication 76948002
Allergic conjunctivitis indication 473460002 DOID:11204
Acute postoperative pain indication 107401000119105
Postoperative Ocular Pain indication
Post-Op Ocular Inflammation indication
Post-Op Photophobia indication
Renal colic off-label use 7093002
Peptic ulcer contraindication 13200003 DOID:750
Disorder of cornea contraindication 15250008 DOID:10124
Acute gastric ulcer with perforation contraindication 19850005
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Tear film insufficiency contraindication 46152009
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Corneal erosion contraindication 50792001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Rheumatoid arthritis contraindication 69896004 DOID:7148
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Hemophilia contraindication 90935002
Corneal degeneration contraindication 111521006 DOID:1237
Perioperative care contraindication 133897009
Asthma contraindication 195967001 DOID:2841
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Smokes tobacco daily contraindication 449868002
Preoperative Pain Management contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.47 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.3% BASE OMIDRIA OMEROS N205388 May 30, 2014 RX SOLUTION IRRIGATION 8173707 July 30, 2023 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
EQ 0.3% BASE OMIDRIA OMEROS N205388 May 30, 2014 RX SOLUTION IRRIGATION 9278101 July 30, 2023 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8207215 May 28, 2024 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8377982 May 28, 2024 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8541463 May 28, 2024 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8906950 May 28, 2024 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8946281 May 28, 2024 A METHOD OF TREATING OCULAR PAIN
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 9216167 May 28, 2024 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8008338 May 24, 2027 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.3% BASE OMIDRIA OMEROS N205388 May 30, 2014 RX SOLUTION IRRIGATION Dec. 8, 2020 NEW PATIENT POPULATION
EQ 0.3% BASE OMIDRIA OMEROS N205388 May 30, 2014 RX SOLUTION IRRIGATION June 8, 2021 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 9.72 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.90 WOMBAT-PK CHEMBL
Aldose reductase Enzyme IC50 5.21 DRUG MATRIX
Prostaglandin-H2 D-isomerase Enzyme IC50 6.64 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 4.94 CHEMBL

External reference:

IDSource
4028637 VUID
N0000178380 NUI
C0073631 UMLSCUI
D00813 KEGG_DRUG
4EVE5946BQ UNII
74103-07-4 SECONDARY_CAS_RN
108512006 SNOMEDCT_US
4028637 VANDF
004812 NDDF
35827 RXNORM
372501008 SNOMEDCT_US
d00273 MMSL
CHEBI:6129 CHEBI
CHEMBL469 ChEMBL_ID
DB00465 DRUGBANK_ID
KTR PDB_CHEM_ID
5558 INN_ID
3826 PUBCHEM_CID
CHEMBL1201124 ChEMBL_ID
D020910 MESH_DESCRIPTOR_UI
D020911 MESH_DESCRIPTOR_UI
6661 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acular HUMAN PRESCRIPTION DRUG LABEL 1 0023-2181 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 14 sections
ACUVAIL HUMAN PRESCRIPTION DRUG LABEL 1 0023-3507 SOLUTION/ DROPS 4.50 mg OPHTHALMIC NDA 14 sections
ACULAR LS HUMAN PRESCRIPTION DRUG LABEL 1 0023-9277 SOLUTION/ DROPS 4 mg OPHTHALMIC NDA 13 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0093-0314 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0069 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0072 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0076 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0378-1134 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-2287 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-2288 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3793 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3795 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3796 INJECTION, SOLUTION 60 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0548-9021 INJECTION 30 mg INTRAMUSCULAR ANDA 16 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6041 INJECTION 15 mg INTRAMUSCULAR ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6042 INJECTION 30 mg INTRAMUSCULAR ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6043 INJECTION 30 mg INTRAMUSCULAR ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 10544-222 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 12634-809 TABLET 10 mg ORAL ANDA 13 sections
ACULAR HUMAN PRESCRIPTION DRUG LABEL 1 16590-002 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 10 sections
KETOROLAC HUMAN PRESCRIPTION DRUG LABEL 1 16590-138 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-376 SOLUTION 5 mg OPHTHALMIC ANDA 11 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-207 SOLUTION/ DROPS 4.50 mg OPHTHALMIC ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-208 SOLUTION 4 mg OPHTHALMIC ANDA 13 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-209 SOLUTION 5 mg OPHTHALMIC ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-432 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
ACULAR HUMAN PRESCRIPTION DRUG LABEL 1 21695-463 SOLUTION 5 mg OPHTHALMIC NDA 10 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-588 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-624 SOLUTION 4 mg OPHTHALMIC ANDA 10 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-985 SOLUTION 4 mg OPHTHALMIC ANDA 11 sections